Indian stocks: Visit www.stage2stocks.com →

Ernexa Therapeutics Inc.

Stage 4 · Declining · week 13

As of Oct 22, 2026, Ernexa Therapeutics is in Stage 4, the downtrend phase, now in week 13 (since Jul 28, 2026). It closed at $2.08, 95.6% below its 52-week high and below its 200-day average, which is falling.

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. More about the company

$2.08
-1.42% today
$3.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ERNA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S3 13w
S4 62w
S4 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 5w → S4 17w → S1 12w → S2 8w → S3 13w → S4 62w → S1 8w → S4 18w → S1 10w → S4 12w current
Total tracked: 166 weeks across 10 stage runs.

ERNA among Biotechnology515th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…515ERNAStage 4 · wk 136−43.0%
vs 52W High
-95.6%
$1.98 lo$47.00 hi
95.6% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 13
1w13w26w
Week 13, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-74.8%
200 DMA: $8.26 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.30x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-43.0%
3M
-47.1%
6M
-56.2%
YTD
-92.8%
1Y
-93.1%
Scan Membership
Breakout Watch
Latest: 2024-04-11
6 appearances in last 60 days. First seen: 2019-04-26.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 13 · Vol 0.30x
2026-10-21S4
Wk 13 · Vol 0.14x
2026-10-20S4
Wk 12 · Vol 0.85x
2026-10-19S4
Wk 12 · Vol 0.79x
2026-10-16S4
Wk 12 · Vol 0.44x
2026-10-15S4
Wk 12 · Vol 0.11x
2026-10-14S4
Wk 12 · Vol 0.17x
2026-10-13S4
Wk 11 · Vol 0.13x
2026-10-12S4
Wk 11 · Vol 0.51x
2026-10-09S4
Wk 11 · Vol 0.78x
2026-10-08S4
Wk 11 · Vol 3.80x
2026-10-07S4
Wk 11 · Vol 15.10x
Moving averages & range
50 DMA
$3.58
200 DMA
$8.26
52W High
$47.00
52W Low
$1.98
5D Low
$1.98
Resistance levels (recent highs)
20d High
$3.47
60d High
$5.04
120d High
$13.63
250d High
$47.00
Next resistance
+66.8%
to 20d High
ROE
-320.7%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.8

Ernexa Therapeutics: quick answers

What stage is Ernexa Therapeutics in?

As of Oct 22, 2026, Ernexa Therapeutics (ERNA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 28, 2026 and is in week 13. What the four stages mean

Is Ernexa Therapeutics in an uptrend?

No. Ernexa Therapeutics is in a Stage 4 downtrend. It trades 74.8% below its 200-day average, which is falling.

How far is Ernexa Therapeutics from its 52-week high?

Ernexa Therapeutics closed at $2.08 on Oct 22, 2026, 95.6% below its 52-week high of $47.00. Its 52-week low is $1.98.

How has Ernexa Therapeutics performed over the past year?

As of Oct 22, 2026, Ernexa Therapeutics is down 93.1% over the past year and down 92.8% so far in 2026.

Which sector and industry is Ernexa Therapeutics in?

Ernexa Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.